brelovitug Updated Nov 10
Brelovitug has cleared its two pivotal Phase 3 trials (AZURE-1 and AZURE-4), setting up a BLA submission in H1 2027. The stock already reflects significant optimism (analyst mean target $155 vs ~$94 close), and the next major binary event is the BLA acceptance and subsequent FDA review. Watch for the AZURE-2 head-to-head data against Gilead's Hepcludex, which will determine brelovitug's commercial positioning in a market with one existing approved therapy.
- Brelovitug has now succeeded in two pivotal Phase 3 trials (AZURE-1 and AZURE-4), de-risking its regulatory path significantly. The drug has FDA Breakthrough Therapy and Orphan Drug designations, which could accelerate review. Long-term data showing 100% response in cirrhosis patients is a strong differentiator. Mirum already has a commercial infrastructure and ~$715-720M in annual product sales from approved drugs (Livmarli, bile acid medicines), meaning it can fund the launch without dilutive financing. Analyst consensus is Strong Buy with a mean price target of $155, implying ~66% upside from the November 10 close of $94.42.
- Gilead's Hepcludex (bulevirtide) was approved by the FDA in May 2026 as the first and only approved treatment for chronic HDV, giving it first-mover advantage and established physician familiarity. The AZURE-2 trial is a head-to-head comparison against Hepcludex, and brelovitug's commercial differentiation versus Hepcludex is unproven. HDV is a very small market (estimated ~100,000 patients in the US), limiting peak sales potential. BLA submission is still months away (H1 2027), and the stock already reflects significant gains (up ~13% on orphan drug news alone). Insider sales by CEO Christopher Peetz sold $1.8M of stock on November 4, 2026 at $90/share.